Molina Healthcare (MOH) Faces A Fair Value Test, Is The Stock Fully Priced?
Molina Healthcare (MOH) recently caught investor attention after reporting annual revenue of US$42.5b alongside a net loss of US$7m, prompting fresh questions about how the stock’s recent performance lines up with its fundamentals.
See our latest analysis for Molina Healthcare.
Molina Healthcare’s share price has been volatile recently, with a 2.38% 1-day share price return and a 14.93% decline over 30 days, yet a 10.08% year-to-date share price return and 25.21% 1-year total shareholder return that hint at improving momentum despite weaker multi year total returns.
If Molina Healthcare has you rethinking your watchlist, this could be a useful moment to look at other opportunities in healthcare focused technology and data, starting with 42 healthcare AI stocks.
Given Molina Healthcare’s recent share price swings, a US$42.5b revenue base and a small net loss, the next step is clear: Do current valuations still leave enough upside to justify the risks you would be taking?
Most Popular Narrative: 2% Overvalued
Molina Healthcare’s most followed narrative points to a fair value of $191.76 per share, slightly below the last close of $196.45. This puts the focus on whether the story justifies that gap.
Molina's acquisition pipeline, comprising many actionable opportunities, could lead to accretive additions and contribute to future earnings. Their strategy to deploy capital in acquisitions is expected to support EPS growth.
Want to see what sits behind that earnings build up. The narrative leans heavily on projected revenue expansion, margin repair and a future earnings multiple that assumes consistent execution. Curious which specific financial steps need to fall into place for that to hold.
Result: Fair Value of $191.76 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Molina Healthcare still faces real pressure points if Medicaid funding tightens or if changes to Marketplace subsidies and risk adjustment weigh more heavily on membership and margins.
Find out about the key risks to this Molina Healthcare narrative.
Another View On Molina Healthcare’s Valuation
The narrative around Molina Healthcare centers on a fair value of $191.76 per share that screens as slightly overvalued against the current price. Yet on simple sales based metrics, the picture looks very different.
Molina Healthcare trades on a P/S ratio of 0.2x, while the wider US Healthcare industry sits at 1.4x and close peers average 2.2x. The fair ratio is 0.8x. That gap suggests the market may be pricing in real business and policy risks, but it also raises a clear question for investors: Is this just caution, or is the stock being discounted more than the fundamentals warrant?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Molina Healthcare presenting both questions and opportunities, it makes sense to review the full picture for yourself and move quickly while sentiment is mixed. You can start by weighing up the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Molina Healthcare?
If Molina Healthcare has sharpened your focus on quality, do not stop here. Use the Simply Wall St Screener now so you do not miss other compelling opportunities.
- Spot potential value opportunities early by scanning companies that pass tight valuation and quality filters with the 49 high quality undervalued stocks.
- Prioritise resilience by focusing on companies that pair modest risk profiles with dependable fundamentals through the 78 resilient stocks with low risk scores.
- Hunt for under the radar potential by zeroing in on lesser known companies that still show strong financial quality using the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com